591 related articles for article (PubMed ID: 9611063)
1. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
2. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
3. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
Giurgea NL; Pitrop M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
[TBL] [Abstract][Full Text] [Related]
4. Low-malignant potential epithelial tumors of the ovary: a clinicopathological study.
Hassan E; Koumantaki Y; Stefanaki K; Matalliotakis I; Koumantakis E
Eur J Gynaecol Oncol; 1998; 19(2):170-2. PubMed ID: 9611060
[TBL] [Abstract][Full Text] [Related]
5. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
6. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
9. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
Zhang W; Wang L; Xin Z
Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
[TBL] [Abstract][Full Text] [Related]
10. [The clinicopathological features and risk factors of recurrence in patients with mucinous borderline ovarian tumors].
Sun L; Song Y; Li N; Yuan GW; Sun YC; Li N; Ma SK; Zhang X; Wu LY
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):589-594. PubMed ID: 28835081
[No Abstract] [Full Text] [Related]
11. Mucinous carcinoma of the ovary. Clinicopathologic analysis.
Kikkawa F; Kawai M; Tamakoshi K; Suganuma N; Nakashima N; Furuhashi Y; Kuzuya K; Hattori S; Arii Y; Tomoda Y
Oncology; 1996; 53(4):303-7. PubMed ID: 8692534
[TBL] [Abstract][Full Text] [Related]
12. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
13. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
Fan HY; Duan DM; Liu YF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
[TBL] [Abstract][Full Text] [Related]
15. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
16. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
17. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
Cho HY; Kyung MS
Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
[TBL] [Abstract][Full Text] [Related]
18. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
[TBL] [Abstract][Full Text] [Related]
19. [Borderline ovarian tumors].
Ivanov S
Akush Ginekol (Sofiia); 2002; 42(1):23-5. PubMed ID: 11935694
[TBL] [Abstract][Full Text] [Related]
20. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
Chiesa AG; Deavers MT; Veras E; Silva EG; Gershenson D; Malpica A
Int J Gynecol Pathol; 2010 Mar; 29(2):108-12. PubMed ID: 20173495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
